(Health Korea News / Soon-ho Lee) The scale of the contract development and manufacturing (CDMO) business in the domestic pharmaceutical industry is rapidly growing. While quite a few pharmaceutical companies have already entered the related market, companies that entered the CDMO market early also appear to be expanding their business further by expanding additional facilities through M&As.
#huonsrecently decided to acquire 2,647,378 shares of Pangene for 14.3 billion won to expand its biopharmaceutical contract development and manufacturing (CDMO) business. Stock acquisition is carried out through acquisition of old shares and paid-in capital increase through allocation to a third party.
The company also plans to acquire new shares issued by Panzen. After acquiring the stake, Huons holds a total of 3,983,167 shares of Pangen, becoming the largest shareholder with a 31.53% stake. Once the stock acquisition is completed, Huons plans to secure management rights and incorporate it as a subsidiary through Pangene’s extraordinary general shareholders’ meeting.
Huons plans to strengthen its biopharmaceutical R&D and biopharmaceutical CDMO business through the acquisition of Pangene. Pangen has Good Manufacturing Practices (GMP) facilities for biopharmaceutical production, Pangen CHO-TECH, the original technology for cell line development, and commercialization capabilities.
#Celltriondecided to establish a corporation as a 100% subsidiary of Celltrion within this year to expand its CDMO business.
Celltrion Group Chairman Seo Jeong-jin and his eldest son Seo Jin-seok, CEO of Celltrion’s management division, recently announced at the Morgan Stanley Global Healthcare Conference that they will pursue a plan to secure production facilities, operate them as a 100% owned subsidiary, and utilize them for CDMO business.
Celltrion’s goal is to secure competitiveness beyond existing CDMO companies based on low expansion costs and high productivity while utilizing its own antibody development and production know-how.
Currently, detailed discussions on the details of the business are in progress, and we plan to begin facility expansion and sales activities in earnest starting next year.
#SK Biosciencesigned a contract with Klocke Group, a German pharmaceutical and bio company, to acquire a management stake in ‘IDT Biologika’ last June. IDT Biologica is a German vaccine consignment production company, and SK Bioscience successfully completed the acquisition process last month.
SK Bioscience’s goal is to grow into a company with consolidated sales of KRW 1 trillion within 5 years based on the growth of IDT Biologica.
To this end, the top priority is to seek ways to maximize the operation rate of IDT Biologica’s production facilities. The plan is to build large-scale vial manufacturing facilities among IDT Biologica’s various DS (drug substance) and DP (finished drug product) production facilities as an infrastructure for winning large-scale projects centered on global pharmaceutical companies.
The goal of the freeze-dried vial manufacturing line is to optimize the extension of existing contracted projects and winning orders for promising clinical pipelines and commercially viable late-stage clinical CGT projects. By securing additional cell line manufacturing technology and recombinant vaccine development capabilities, we plan to pursue new CDMO contracts for mid- to large-sized products.
#Daewoong BioIn order to secure biopharmaceutical production capacity, it will build a cGMP-level bio factory and expand its microorganism-based biopharmaceutical CMO business. In particular, we believe that the microbial-based genetic recombinant medicine market among biopharmaceutical products will continue to grow, and we are targeting this market.
Daewoong Bio is pursuing the establishment of a cGMP-level bio factory with cost and quality competitiveness in order to strengthen its production capacity for microorganism-based genetic recombinant drugs and secure future growth engines. Daewoong Bio’s bio factory, which began construction in March of last year, is aiming for large-scale GMP approval from the Ministry of Food and Drug Safety in 2027 and US FDA approval in 2028 after completion in August.
In a situation where most CMO businesses are operated based on animal cells, Daewoong Bio is also preparing to move beyond CMO for microorganism-based genetic recombinant drugs to become a specialized contract development and manufacturing (CDMO) company.
Biopharmaceutical production is measured based on the capacity of the incubator used in the cell culture process, and Daewoong Bio has secured a production capacity of 1000L, the second largest in Korea.
Besides this #BoryeongThe plan is to lay the foundation for a global pharmaceutical mass contract development and manufacturing (CDMO) business by expanding the business model of acquiring, supplying, and distributing strategically essential drugs to overseas markets.
An industry official said, “A few years ago, there was a strong perception that the CDMO business should be handled by specialized companies, but recently it has become a business field that even general pharmaceutical companies are rushing into.” He added, “As securing new facilities is expensive and requires business know-how, CDMO “The number of cases of corporate acquisitions is also increasing,” he said.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
